Skip to content
← All supplements
NAC
The Master Antioxidant Precursor

NAC

N-Acetyl Cysteine

Key Benefits

Glutathione Production

The body uses it to make glutathione. That is a biochemical role, not a cleanse.

Liver Support

Clinical use for acetaminophen overdose is a hospital treatment. It does not mean a capsule protects the liver or cleanses it.

Respiratory Health

Breaks down mucus and supports lung function, used clinically for respiratory conditions.

Mental Health

May reduce obsessive-compulsive and addictive behaviors through glutamate modulation.

auto_awesome

Activation Synergies

recommended Vitamin C

Vitamin C works synergistically with NAC to support glutathione production and enhance overall antioxidant defense.

recommended Selenium

Selenium is required for glutathione peroxidase activity. Together with NAC, they create a powerful glutathione-based antioxidant system.

optional Glycine

Glycine is another precursor to glutathione. Combined with NAC, they ensure optimal glutathione synthesis.

Recommended Dosage

medical_services
600-1800 mg / daily

Take on empty stomach for best absorption. May cause sulfur-like odor. Start with lower doses to assess tolerance. Effects build over weeks.

warning

Deficiency Indicators

  • Chronic oxidative stress
  • Liver issues or exposure to toxins
  • Respiratory congestion
  • Low glutathione levels
verified

Scientific Citations

Examine.com open_in_new

N-Acetylcysteine: Research Summary

Research & Sources

What the evidence says — with links to the original studies

Consensus: emerging

N-acetylcysteine (NAC) is a cysteine derivative and glutathione precursor with a strong, established evidence base in two clinical domains and a growing but mixed body of evidence in a third. As a glutathione replenisher it is the first-line, life-saving antidote for acetaminophen (paracetamol) overdose, dramatically reducing hepatotoxicity when given early (within 8-10 hours of ingestion). As a mucolytic/antioxidant it has a Cochrane-supported role in chronic bronchitis/COPD, where pooled data show a modest reduction in exacerbations, though the benefit is driven partly by older trials and a large 2023 meta-analysis found no significant effect on exacerbations or lung function. In psychiatry, NAC has been studied as an adjunct across OCD and related disorders (trichotillomania, skin-picking), substance-use craving, schizophrenia, and mood disorders; the evidence is emerging and inconsistent, with the strongest signals for schizophrenia adjunct and substance craving, and mixed/underpowered results for OCD and mood disorders. NAC is generally safe and well tolerated. Its US regulatory status is contested: because NAC was approved as a drug (1963) before being marketed as a supplement, the FDA has stated it is technically excluded from the dietary-supplement definition, and since 2022 permits sales only under enforcement discretion.

check_circle

Supporting Evidence

Cochrane systematic review Cochrane Database of Systematic Reviews (CD001287.pub6), 2019

Mucolytics (including NAC) reduce exacerbations vs placebo; about 8 people need treatment for 9 months for one extra person to avoid a flare-up, with slightly fewer disability days. Moderate certainty; benefit larger in older (1970s-90s) trials.

Peer-reviewed review Livers, 2025 (open access)

Confirms NAC as glutathione precursor and antidote that neutralizes the toxic metabolite NAPQI. Severe hepatotoxicity in only ~6.1% when treated within 10 hours vs ~41% when delayed beyond 16 hours; near-universal recovery with early treatment.

Systematic review & meta-analysis of RCTs Frontiers in Psychiatry, 2024 (open access)

Six RCTs, 195 patients. NAC added to SSRIs may benefit patients with moderate-to-severe OCD over 5-8 weeks; benefit not significant for very short or >12-week durations. Calls for larger multi-center trials.

Narrative/evidence review BioMed Research International, 2018 (open access)

Strongest evidence for schizophrenia adjunct; moderate evidence for substance (cocaine/cannabis) craving reduction; OCD and mood disorders mixed/inconsistent. NAC safe and well tolerated at ~2000-2400 mg/day. Open-access full text also at moodclinic.ca.

Systematic review & meta-analysis Therapeutic Advances in Respiratory Disease, 2023 (open access)

9 RCTs, 2,137 patients (doses 600 mg/day to 1,800 mg twice daily). Included here for completeness of the respiratory evidence, though its primary result was null (see opposing sources).

info

Opposing / Critical Views

Systematic review & meta-analysis Therapeutic Advances in Respiratory Disease, 2023 (open access)

Across 6 exacerbation studies (1,944 patients) NAC did NOT reduce acute exacerbations (OR 1.12, 95% CI 0.92-1.36, p=0.26) and showed no significant effect on FEV, vital capacity, quality of life, or glutathione. Contrasts with the Cochrane review's modest positive finding, underscoring a mixed respiratory picture.

Randomized controlled trial Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP), 2013

Placebo-controlled add-on RCT in children/adolescents; NAC did not separate from placebo for pediatric hair-pulling, contrasting with an earlier positive adult trichotillomania RCT (Grant et al. 2009). Illustrates the inconsistent, population-dependent psychiatric evidence.

Educational summary of published research — not medical advice. Consult a qualified professional before supplementing.

groups

Have You Tried This?

Join our collective laboratory. Share your experience level with this topic and help others gauge the journey.

Based on .

No one has shared yet. Be the first to place a pin on the map.

check_circle You marked yourself as .

Status: In Your Stack Status: Not in Stack